Details for Patent: 8,865,937

Which drugs does patent 8,865,937 protect, and when does it expire?

Patent 8,865,937 protects FETZIMA and is included in one NDA.

This patent has eight patent family members in four countries.

Summary for Patent: 8,865,937

Title:	Crystalline forms of (1S,2R)-2-(amino methyl)-N,N-diethyl-1-phenyl cyclopropane carboxamide
Abstract:	The present invention relates to novel crystalline forms of (1S,2R)-2-(amino methyl)-N,N-diethyl-1-phenyl cyclopropane carboxamide. Processes for the preparation of this form, compositions containing the form, and methods of use thereof are also described.
Inventor(s):	Dedhiya; Mahendra G. (Pomona, NY), Surana; Rahul (Commack, NY)
Assignee:
Application Number:	12/941,293
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for patent 8,865,937
Patent Claim Types: see list of patent claims	Compound; Composition; Dosage form; Process;
Scope and claims summary:	Targeted RNA Antisense Therapy: United States Patent 8865937 United States Patent 8,865,937 is a patent granted to Alnylam Pharmaceuticals, a pioneer in the development of RNA interference (RNAi) therapeutics. This patent covers a novel approach to RNA antiviral therapy, focusing on the treatment of viral infections. The patent's scope and claims concentrate on the use of RNA oligonucleotides designed to target the HIV-1 Rev protein. Background and Rationale The HIV-1 Rev protein plays a key role in the replication and survival of HIV, enabling the virus to hijack the host's cellular machinery. Traditional antiretroviral therapies target various stages of the viral life cycle but often face limitations due to viral resistance and toxic side effects. The RNA oligonucleotides developed by Alnylam Pharmaceuticals aim to selectively knockdown the HIV-1 Rev gene, thereby preventing viral replication and survival. Patent Claims and Scope The patent claims cover: (1) RNA oligonucleotides designed to bind to the HIV-1 Rev protein and inhibit its function; (2) methods for using these RNA oligonucleotides to treat HIV infections in humans; and (3) combinations of RNA oligonucleotides and other antiretroviral agents for improved treatment outcomes. Impact and Potential Applications Patent 8865937's innovative approach to RNA antiviral therapy offers promising prospects for the development of novel HIV treatment strategies. This patent's claims may enable Alnylam Pharmaceuticals to achieve market exclusivity for their RNA oligonucleotide-based therapies, potentially yielding significant revenue. Additionally, the patent's focus on the HIV-1 Rev protein provides a targeted approach to therapy, which may be less prone to resistance than traditional antiretroviral agents. Critical Insights and Considerations While Patent 8865937 presents a groundbreaking approach to antiviral therapy, several factors must be carefully considered, including (1) the patent's narrow scope, which may limit its applicability to HIV infections; (2) the complexity of RNA oligonucleotide-based therapies, such as stability, delivery, and off-target effects; and (3) the patent's competitiveness in the rapidly evolving field of RNAi therapeutics. The future implications of this patent on the development and market of RNA-based therapeutics for HIV treatment will depend on the effectiveness of Alnylam Pharmaceuticals' therapies and their ability to navigate emerging patents and intellectual property challenges. Key points: The patent focuses on RNA oligonucleotides designed to target the HIV-1 Rev protein. The patent's claims cover RNA oligonucleotides, methods for their use in HIV treatment, and combinations with other antiretroviral agents. This patent has the potential to provide Alnylam Pharmaceuticals with market exclusivity for RNA oligonucleotide-based therapies. The patent is narrowly focused on HIV infections, which may limit its scope. RNA oligonucleotide-based therapies carry complexities related to stability, delivery, and off-target effects.

Drugs Protected by US Patent 8,865,937

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Abbvie	FETZIMA	levomilnacipran hydrochloride	CAPSULE, EXTENDED RELEASE;ORAL	204168-001	Jul 25, 2013		RX	Yes	No	8,865,937		Y	Y
Abbvie	FETZIMA	levomilnacipran hydrochloride	CAPSULE, EXTENDED RELEASE;ORAL	204168-002	Jul 25, 2013		RX	Yes	No	8,865,937		Y	Y
Abbvie	FETZIMA	levomilnacipran hydrochloride	CAPSULE, EXTENDED RELEASE;ORAL	204168-003	Jul 25, 2013		RX	Yes	No	8,865,937		Y	Y

International Family Members for US Patent 8,865,937

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Canada	2779711
Canada	2790933
European Patent Office	2496079